COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.
Citation: Srikanth Umakanthan, Vijay Kumar Chattu, Anu V Ranade, Debasmita Das, Abhishekh Basavarajegowda, Maryann Bukelo. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19[J]. AIMS Public Health, 2021, 8(1): 137-153. doi: 10.3934/publichealth.2021011
[1] | Marina Santiago, Lindsay Eysenbach, Jessica Allegretti, Olga Aroniadis, Lawrence J. Brandt, Monika Fischer, Ari Grinspan, Colleen Kelly, Casey Morrow, Martin Rodriguez, Majdi Osman, Zain Kassam, Mark B. Smith, Sonia Timberlake . Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study. AIMS Microbiology, 2019, 5(1): 1-18. doi: 10.3934/microbiol.2019.1.1 |
[2] | Alejandro Borrego-Ruiz, Juan J. Borrego . Human oral microbiome and its influence on mental health and brain disorders. AIMS Microbiology, 2025, 11(2): 242-294. doi: 10.3934/microbiol.2025013 |
[3] | Paola Brun . The profiles of dysbiotic microbial communities. AIMS Microbiology, 2019, 5(1): 87-101. doi: 10.3934/microbiol.2019.1.87 |
[4] | Sunarno Sunarno, Nelly Puspandari, Fitriana Fitriana, Uly Alfi Nikmah, Hasta Handayani Idrus, Novaria Sari Dewi Panjaitan . Extended spectrum beta lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae in Indonesia and South East Asian countries: GLASS Data 2018. AIMS Microbiology, 2023, 9(2): 218-227. doi: 10.3934/microbiol.2023013 |
[5] | Kerri Glassner, Eamonn MM Quigley, Lissa Franco, David W Victor III . Autoimmune liver disease and the enteric microbiome. AIMS Microbiology, 2018, 4(2): 334-346. doi: 10.3934/microbiol.2018.2.334 |
[6] | George L. Mendz, Nadeem O. Kaakoush, Julie A. Quinlivan . New techniques to characterise the vaginal microbiome in pregnancy. AIMS Microbiology, 2016, 2(1): 55-68. doi: 10.3934/microbiol.2016.1.55 |
[7] | Dawn B. Goldsmith, Zoe A. Pratte, Christina A. Kellogg, Sara E. Snader, Koty H. Sharp . Stability of temperate coral Astrangia poculata microbiome is reflected across different sequencing methodologies. AIMS Microbiology, 2019, 5(1): 62-76. doi: 10.3934/microbiol.2019.1.62 |
[8] | Rayane Chettaoui, Gilles Mayot, Loris De Almeida, Patrick Di Martino . Cranberry (Vaccinium macrocarpon) dietary supplementation and fecal microbiota of Wistar rats. AIMS Microbiology, 2021, 7(2): 257-270. doi: 10.3934/microbiol.2021016 |
[9] | Neetu Sharma, Sonu Bhatia, Abhinashi Singh Sodhi, Navneet Batra . Oral microbiome and health. AIMS Microbiology, 2018, 4(1): 42-66. doi: 10.3934/microbiol.2018.1.42 |
[10] | Mohammad Shamim Ahasan, Thomas B. Waltzek, Leigh Owens, Ellen Ariel . Characterisation and comparison of the mucosa-associated bacterial communities across the gastrointestinal tract of stranded green turtles, Chelonia mydas. AIMS Microbiology, 2020, 6(4): 361-378. doi: 10.3934/microbiol.2020022 |
COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.
The Human Microbiome Project (HMP) launched in 2008 ushered in a new era of understanding the microbial communities residing with us. Until then, we did not realize that microorganisms outnumbered our cells by tenfold, and a great majority were unknown because they have yet to be cultured and studied [1]. The HMP enabled numerous results and insights into the intricate and important roles these microbes play in our health, ranging from metabolism and phenotype modulation (such as obesity), innate immune system development, to etiology for diseases or conditions (due to microbial ecosystem imbalance) [2,3]. New findings challenge our current thinking and approaches, and they prompt paradigm shift towards alternative solutions in disease diagnosis, prevention, and treatments.
The HMP focused on five sites: gastrointestinal, oral, skin, nasal and urogenital. Urinary system was not part of the study because traditionally urine was considered sterile in healthy individuals [4,5,6,7,8]. This observation dated back to the mid 1800's when microbiology was still in its infancy and it continued to be upheld based on bacterial culturing outcomes. The clinical protocol and conditions for detection, however, only yield limited number and types of bacteria [4]. In the last few years with advanced culturing techniques and molecular approaches, we realized the urinary system contains extensive numbers and members of bacteria in healthy and asymptomatic individuals [9,10,11,12]. They are uniquely different than populations in the gut and vagina, two niches in close proximity from the bladder [5]. Their roles as urinary microbiota in maintaining our health and predisposing to a variety of diseases and disorders are just beginning to be elucidated [4,5,8,13,14].
This review provides a general overview of urinary microbiome, its compositions and associations with different age and gender. The effects of these microbes in the health status are further illustrated by examples of diseases and disorders resulted from changes of microbial communities. The paper concludes with research gaps and future directions of urinary microbiome research.
The clinical dogma, up to very recently, assumed urine from healthy individuals was sterile and the presence of bacteria signified some type of infection in the urinary tract [6]. As a body fluid, urine is hostile to the survival of microorganisms. It is hypertonic with low pH (average around pH 6), contains high concentration of urea which is inhibitory to most bacteria, and other substances including some that possess antimicrobial properties [13]. Additionally, the frequent flushing and voiding make persisting in the bladder difficult. Those that can survive, colonize and cause infection are termed uropathogens, and they often possess virulence factors such as host cell attachments, biofilm formation, host defense evasion, and antimicrobial resistance development [15]. Additional mechanisms to survive in this harsh environment include utilizing urine as substrate for growth, upregulating genes involved in iron transport, and devising systems to adapt in low pH, high urea concentrations and hypertonic environments [13].
Another contributing factor to the long acceptance of urine as sterile was the clinical procedure for detecting bacteria in urine samples. Since the 1950's the gold standard for confirming urinary tract infection (UTI) has been the urine culture. Over the years, this detection method has proven questionable because the urine culture conditions are very restrictive, thus limits in the types of bacteria that are recoverable. The protocol specifies a very small amount of sample (1 μl of urine), plated only on two microbiological media (blood agar and MacConkey agar), and incubated at 35 ℃ for 24 hours. These culture conditions favor fast-growing aerobic bacteria and are designed for uropathogens such as Escherichia (E.) coli. Those that require special nutrient, takes more than 24 hours to grow, or prefer anaerobic environment (bladder is low in oxygen) are frequently missed from this screening [8,11,12,16]. Furthermore, the threshold to indicate a positive urine culture has been debated and changed throughout the years [17]. In general, 105 colony forming units (CFU)/mL indicate UTI; however, some urinary disorders resulted from lower number of organisms ( < 103 CFU/mL) are overlooked by this routine culture method [4,10,16,17].
The advance of molecular techniques enabled a more comprehensive assessment of the microbes present in urine. The 16S ribosomal RNA gene sequence analysis yielded different types of bacteria in healthy urine [4,5,9,10]. In fact, the bladder may include resident bacteria flora such as Lactobacillus, Staphylococcus, Gardnerella, just to name a few [11,12,18]. One study reported a total of 321 genera from bladders of culture-negative women [12]. The disparity between culture and molecular assay prompted the development of Expanded Quantitative Urine Culture (EQUC) [10]. It uses more sample (10 μL or 100 μL) to plate on a variety of media, and incubate under different temperatures and atmospheric conditions [17,19]. A comparison between the clinical microbiology laboratory protocol and EQUC showed 90% false-negative rate for the former gold standard and missed 67% uropathogens overall [10,18,19,20]. Additionally, EQUC helps to determine many of the organisms identified by 16S rRNA gene sequencing are viable and cultivable under the appropriate growth conditions [4,7,10,20]. These findings led to the recommendation of a "streamlined EQUC" as a supplemental test for individuals suspected of UTI but had negative standard urine culture [19].
These emerging evidences dispute that healthy bladder is sterile; rather, the bacterial community found in the urinary system has implications in the health status of an individual [5,8,10,11,21]. Although urine microbiome shared many similar genera with other sites in the body, it is less diverse and lower in number when compare with microbiome found in other physiological systems such as the gut and skin [18]. Nevertheless, the urinary tract is a unique environment niche for microbes, and the new knowledge associated with urinary microbiome opens door to better understanding of urinary system diseases, including implications in obstetrics and gynecology as expressed by a clinical opinion [11].
Studies have indicated the urinary microbiome is distinctive between men and women, likely due to differences in anatomical structures and hormones [5]. In general, females have a more heterogeneous mix of bacterial population than males in their clean catch mid-stream urine samples, reflecting the bladder microbiome determined by 16S rRNA analyses [9]. One study showed significantly higher number of E. coli cultured from healthy adult women (91%) than men (25%) [21]. Lactobacillus species are the most dominant members of urine microbiome in women during child bearing age [22]. Other microbiome identified by molecular method (16S rRNA gene sequencing) in female samples included representative members of the Actinobacteria (e.g., Actinomyces, Arthobacter) and Bacteroidetes (e.g., Bacteroides) phyla which were absent from male samples [9]. When considering the core microbiome with varied abundance in the urinary tract throughout life, both men and women possess three predominant genera-Lactobacillus, Corynebacterium, and Streptococcus [9,23,24].
There were less reports regarding urinary microbiome in men. One study employing 16S rRNA gene sequencing to characterize bacterial communities in urine collected from adolescent men and found the predominant genera as Streptococcus, Gardnerella, Lactobacillus and Veillonella [23]. Another group investigated healthy urine microbiome in both men and women; using 16S rRNA gene sequencing and metaproteomic analyses they reported higher relative abundance of Corynebacterium in men [24]. This genus is considered a common superficial skin flora, and its members possibly residing in the proximal urethra and/or bladder as well as to the distal urethra. Additional findings were Enterococcus, Proteus, Klebsiella, and Aerococcusas more predominate in male urine.
Variation of urinary microbiome between females and males may also stem from the different compositions in their urine. Women produce higher amount of citrate but less calcium and oxalate, whereas males excrete more creatinine [13]. The different constituents may favor certain microbes to survive in this niche, and they in turn contribute to the health status of their hosts. For example, women are more prone to UTI mostly due to anatomical reasons. However, there are evidences indicating microbes may also play a role in the occurring and recurring of UTI (see section 3.1), and their growth is likely promoted by certain substrates and hormones present in the female urine.
Urine microbiome, similar to microbial communities in other physiological systems, changes with the individual's age [5]. Children and adults have different microbiome populations, likely due to urinary metabolites from diet change, personal hygiene and voiding habits. There are different bacterial genera within age groups among the adults [9]. Changes in hormones may have an influence in the microbiome [25]; a few studies indicated Lactobacillus species increased during puberty and decreased after menopause [4,5,19]. The microbiome could change in women who become pregnant, whereas those who are not pregnant seem to have more stable microbial compositions [22]. As one gets older, constipation and urinary incontinence may alter the survival and persistence of microbes. Symptoms of lower urinary tract seem more prevalent as people age [17]. Using molecular analyses (16S rRNA gene amplification), one study noted four genera were exclusive among the elderly (age 70+) irrespective of the gender: Jonquetella, Parvimonas, Proteiniphilum and Saccharofermentans [9]. These are not well known bacteria and only recently named. Common features among them include anaerobic and fastidious nutrient requirements which made cultivation by conventional methods difficult [26,27,28,29]. The implications of these organisms in the elderly urinary microbiome are still unknown and await further studies [5].
The changes in urinary microbiome during one's lifetime have been associated with different diseases, and some will be further discussed in the next section. One example is the decrease of vaginal Lactobacillus spp. in women after menopausal allows colonization of uropathogens, resulting in increased UTI cases [30]. It is interesting to note that recurrent UTIs are not limited to older women; in fact, it is common among young and healthy women as well [31]. There are no obvious reasons for such observation, such as identifiable risk factors or abnormal urinary tracts associated with these occurrences [31]. Another example is catheter users who are at high risk of UTI. Catheter-associated urinary tract infection is a concern for the elderly as it is a common infection in nursing homes. Nevertheless, this type of infection also affects patients in acute care regardless of age [32]. Lastly, the bacteria Oxalobacter formigenes has been demonstrated with a possible role in urolithiasis (i.e., kidney stones) [33]. It's colonization in the gut seems to be age-dependent, present in children up to 8 years old and then starts to decline by age 12 into adulthood [5]. Urolithiasis cases are higher in adults, and some postulate the lower number of O. formigenes along with other factors may contribute to the increased concentration of oxalate in these individuals' urine [34,35].
As the second most common type of infection, UTI accounts for approximately 8.1 million visits to the clinics in 2012 [31,36]. Among them women are more likely to encounter such infections due to anatomical structure (approximately 50% experience UTI in their lifetime), and the elderly with multiple risk factors (e.g., obstruction, poor hygiene, diet and fluid intake) [21]. According to the American Urological Association, an estimated 150 million UTIs occur annually worldwide costing $6 billion in health care [37]. Obviously this disease is wide spread and poses a significant burden to the financial and healthcare systems.
The UTI is commonly associated with E. coli, and it has been implicated in >70% uncomplicated and 25-50% complicated cases [15]. The infection is frequently persistent, and with each UTI the risk of having recurrence increases. For example among women with UTI, 20-25% will develop recurrent infection and 3% within 6 months after treatment [25]. Although E. coli has been considered as the main uropathogen in UTI cases, a prospective study examined individuals with chronic lower urinary tract symptoms found additional organisms associated with these illnesses. Using EQUC and 16S rRNA gene sequencing methods, species of Enterococcus and Staphylococcus were frequently recovered in urine samples regardless of collection methods (clean catch midstream or by catheters) [17]. This suggests the spectrum of bacterial colonization in the urinary tract is broader than previously thought.
There are two types of recurrent infection-relapse and reinfection. The former is caused by the same organism with a shorter interval (within 2 weeks) from the original infection. On the other hand, reinfection is considered a new episode of illness resulted from a different strain of bacteria, and each occurrence is separated by a month after antibiotic treatment [31]. These distinctions were often difficult to discern in the past; however, advanced molecular technologies for bacteria identification now enable strain differentiation which could aid in determining the type of recurrence. This suggests important clinical implications because relapsing infection may result from metabolic, functional or structural abnormalities; thus, requiring more extensive urological evaluation or longer antimicrobial therapy [31].
Reinfection was thought to occur when virulent uropathogens gain entry into the urinary system or re-emerge from the bladder. Among the bacterial species, E. coli are responsible for 80-90% of community-acquired cases [31]. Other etiological agents reported are Staphylococcus saprophyticus, Enterococcus faecalis, Klebsiella pneumoniae, and Proteus mirabilis [12,17]. The EQUC recovered more types of uropathogens that would have been missed from standard culture, an important consideration when half of these microbes were not found in women with UTI symptoms [19]. Molecular techniques allow a wider spectrum of bacterial genomic sequences to be detected, some of these are fastidious or uncultured species [14,31]. As mentioned previously, a number of virulence factors are expressed to invade and colonize their host cells. Uropathogenic E. coli produce 2 types of fimbriae (or pili) that aim at specific receptors on the epithelial cells in the urinary system [31]. Furthermore, these pathogens may develop osmoadaptability to survive under the acidic environmental conditions [15].
There are evidences indicating a reservoir of pathogens may exist in the urinary system, possibly due to frequent failure of antibiotics to completely eradicate uropathogens, or the reemergence of the same organism resulting in recurrent infections [31]. While other microbes residing in the urogenital system are disrupted by antibiotics, pathogens may penetrate deeper to persist and re-infect the host. As E. coli population increases resulting in reinfection, the proportion of Lactobacillus that normally resides in the urogenital system notably decreases [31]. Two species are predominant in healthy women: Lactobacillus (L.) crispatus and L. iners [12,18,19,20]. These organisms play an important role in maintaining the health of urinary tract as their metabolic byproducts (such as lactic acid, hydrogen peroxide) interfere with the adhesion of E. coli by downregulating some virulence factor expressions [5,15,31]. These results prompt replenishing lactobacilli as a strategy to manage recurrent UTIs, and probiotics have been considered due to promising results in maintaining a balanced microbiome in other physiological systems [38]. However, several clinical trials compared the effectiveness of probiotics versus antibiotics with inconclusive results [30]. Nevertheless, the general consensus is probiotic has merits over long term antibiotic treatments, the current method of managing UTIs, and warrants more research in this area. One of the main advantages is the lack of collateral damage, i.e., no increase in resistance rate, when a non-antibiotic prophylaxis is used. Several reports indicated high incidences (up to 100%) of resistance even among asymptomatic individuals when antibiotics were administered [5,30,31]. In some cases, persistence remained even after completion of the course [31].
Urgency urinary incontinence (UUI) is a chronic condition that accounts for 1.5-22% of the US population, mostly affecting women and the elderly [16,20]. Although a proportion of cases resolve after some time, it poses a significant financial burden costing over $76 billion in 2015 [18].
In spite of its prevalence, UUI is a poorly understood urinary condition often attributed to abnormal neuromuscular signaling or functioning [18,20]. Because the symptoms seem to overlap with UTI, it is plausible that microbiome also plays a significant role in UUI [16,18,25]. A prospective cohort study using both culturing (EQUC) and molecular (16S rRNA gene sequencing) methods showed more diversity in women affected by UUI [20]. With combined methods, others reported genera such as Actinobaculum, Actinomyces, Aerococcus, Arthrobacter, and Oligella; many of which contain emerging uropathgoen members (e.g., Aeroccocus urinae, Oligella ureolytica) [11,18] There seems to be a correlation between symptom severity and microbial diversity, as a study using 16S rRNA gene sequencing found increased UUI symptom gravity associated with lower microbial types [25]. In several studies, both women with and without UUI showed Lactobacillus and Gardnerella as the two most dominant genera by molecular techniques; the former plays a protective role as mentioned above, but the latter often associated with bacterial vaginosis [4,14,23]. For Lactobacillus there is additional distinction at the species level-gasseri was more frequent from UUI samples but crispatus more readily encountered from the control [18]. It is unclear how these two species differ in their role in the urinary system. Additional genera recovered by molecular (16S rRNA) and culturing (EQUC) methods in the urinary microbiome are Bifidobacterium, Enterococcus, Actinomyces, Prevotella and Atopobium. These are also present in vaginal tracts which suggest the possibility of a shared urogenital microbiome [14,18]. The protective role of urine microbiome in the bladder and how they influence UUI warrant further studies.
The development of calcium oxalate stones, or urolithiasis, is one of the most common disorders of the urinary tract. It affects 8.8% of the population in the US, and over 300,000 people go to emergency room for such problem each year [39]. Calcium oxalate seems to be the most common type; specifically, oxalate has been reported in 75% of the urinary stones [33]. Oxalate is produced from amino acid metabolism; because it is toxic, it must be excreted by the kidney [33,40]. Epidemiological studies and animal models indicate a correlation between the oxalate excretion and kidney stone development; thus, decreasing dietary oxalate and calcium intake would likely reduce such risk [34].
There have been several postulates regarding the interactions of microbiome and stone formation. One of the associations involved a bacterium, Oxalobacter (O.) formigenes, which was identified with a possible role in reducing recurrent calcium oxalate kidney stone formation [33]. As an anaerobic organism residing in human's intestine, it uses oxalate as main carbon and energy sources [40]. In fact, this bacterium degrades approximately 51% of the dietary oxalate per day and regulates the net intestinal transport of oxalate [41]. Consequently O. formigenes lowers the oxalate concentration for absorption in the colon which in turn decreases the amount excreted from the kidney [33]. As a case in point, colonization of O. formigenes resulted in 70% decrease in the risk of recurrent stone formation [5,34].
Previously, O. formigenes was mostly detected by anaerobic culturing, a time consuming method with varying results. The advancement in molecular techniques (genome sequencing and 16S rRNA gene sequencing) enable more precise assessment of this organism in the microbiome. In the US, the prevalence of O. formigenes is relatively low (31% of population) in adults, perhaps stemmed from common antibiotic usage eliminating this bacterium from the gut [5,40]. This was supported by the absence of O. formigenes in women with recurrent UTI, their frequent antibiotic treatments likely attributed to the increase oxalate excretion. On the other hand, this bacterial population is stable for a period of time (at least up to six months) once colonized. Diets with high oxalate can induce O. formigenes, and there is an interplay between dietary calcium, oxalate and the colonization of O. formigenesthat result in urinary oxalate level of an individual [33,34]. Other organisms (e.g., species of Lactobacillus) have also been implicated in degrading oxalate. However, they are not as efficient as O. formigenes so they will not be further discussed
Another interaction between microbiome and kidney stone was reported by Barr-Beare et al [42]. Although this study only involved 5 young patients, 16S rRNA sequencing and EQUC methods showed the kidney stones contained multiple bacterial taxa. The dominant type (80%) was Enterobacteriaceae, leading the authors to suggest possible association of this bacterial family with pediatric kidney stones. Furthermore, individuals with stones often have higher incidences of UTI. How this observation affects future treatments of both hypercalciuria (high calcium in urine) and UTI awaits additional studies.
Urothelial carcinoma, mostly affecting the bladder, is one of the most common cancers in the urinary system [43]. It accounted for approximately 77, 000 new cases with more than 16,000 deaths in 2016 [44]. Among the risk factors is chronic urinary tract infections especially in the bladder. Because microbiota have been involved in cancers of other organs, it is conceivable that they may play a role in urothelial carcinoma [5,43].
One such study utilizing sequencing technology, albeit with a small sample size, showed the average genera found in cancer patients were noticeably higher than those healthy individuals (73.1 ± 42.8 versus 42.6 ± 19.4) [43]. Acinetobacter was the predominant genus and Streptococcus population was considerably elevated in cancer samples. These results indicate possible association between altered microbiota, both in population types and numbers, and urothelial carcinoma.
On the other hand, microbiota in the bladder may be involved in the prevention of recurrent superficial bladder cancer [5]. Some evidences indicated L. casei could reduce superficial bladder cancer recurrence, leading to considerations in applying probiotics as an alternative therapy [5]. The mechanism of action and interactions of lactobacilli with different microbial populations, however, remain as knowledge gaps.
Assessing microbiome in the urinary system has been a recent development, after expanded culturing technique and molecular analyses disputed the traditional thinking that urine was sterile. This review provided an overview of urinary microbiome and highlighted microbial members play an important role in urinary health of individuals. Understanding urinary microbiome, therefore, allows a more holistic approach in the diagnosis, treatment, and prevention of diseases and disorders in this system [17,20].
There are various gaps that await further studies in urinary microbiome; such as mechanism of colonization (both beneficial organisms and uropathogens), predisposition for disorders due to certain microbial species, and the interplay between diets, probiotics, and other microorganisms. Because of its proximity to other physiological niches, the association between urinary microbes and other microbiomes (gut, genital) may enable a comprehensive assessment of certain diseases (e.g., kidney stone, chronic kidney diseases, bladder cancer) [5,43]. An example is how carcinogens produced in the gut, filtered by the kidneys, and stored in the bladder prior to excretion influence urinary microbiota. A better understanding in these areas will aid in effective and more precise treatments in the future.
Most of the studies cited in this review were conducted with 16S rRNA gene sequencing as their molecular analysis method. Although powerful, its utility in comprehensive assessments of microbiome has certain limitations. For incidence, primers designed from this genetic region specifically target bacteria and at times only capable of genus level identification [10]. On the other hand, whole genome sequencing and metagenomics analyses are highly sensitive in detecting organisms present in individuals. This was demonstrated by the study of Barnett et al. when assessing O. formigenes in healthy young adults [34]. Analyzing the complete genome content of a sample is also broader in scope and allows distinguishing members of the entire microbial communities including viruses, fungi, and parasites. It is even capable of detecting species that are low in numbers which may be overlooked by other molecular methods. Furthermore, the genomic data facilitate studies of genetic composition to understand how organisms respond to different environments (e.g., antibiotics, stress) and their mechanisms to colonize the urinary systems [41]. Next generation sequencing technology and deep sequencing will enable the elucidation of core microbial populations and ascertain their roles in the urinary tract system [43]. This information potentially could lead to early indicators for diseases and the development of diagnostic tests.
Urinary microbiome research comes at the right time as a National Microbiome Initiative announced in 2016 aims at promoting integrated microbiome studies across different ecosystems by engaging interdisciplinary teams [45]. The Initiative also mentioned new platform technologies, among them is whole genomic sequencing which continues to advance significantly and its cost reduced considerably in recent years. This technology is no longer limited to big research and commercial laboratories. Bioinformatics capability has also expanded substantially to address the emergent needs of processing large amount of sequencing data and performing analysis in a timely manner. Numerous tools are being developed with many available as open source for use in the community. Opportunities and potential are plentiful for future studies in urinary microbiome.
The author declares no conflict of interest in this paper.
[1] |
Pooladanda V, Thatikonda S, Godugu C (2020) The current understanding and potential therapeutic options to combat COVID-19. Life Sci 254: 117765. doi: 10.1016/j.lfs.2020.117765
![]() |
[2] |
Wang H, Li X, Li T, et al. (2020) The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 39: 1629-1635. doi: 10.1007/s10096-020-03899-4
![]() |
[3] |
Li H, Liu SM, Yu XH, et al. (2020) Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 55: 105951. doi: 10.1016/j.ijantimicag.2020.105951
![]() |
[4] | Wu J, Deng W, Li S, et al. (2020) Advances in research on ACE2 as a receptor for 2019-nCoV. Cell Mol Life Sci 1-14. |
[5] | Umakanthan S, Sahu P, Ranade AV, et al. (2020) Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J 96: 753-758. |
[6] |
Fu L, Wang B, Yuan T, et al. (2020) Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect 80: 656-665. doi: 10.1016/j.jinf.2020.03.041
![]() |
[7] |
Iyer M, Jayaramayya K, Subramaniam MD, et al. (2020) COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep 53: 191-205. doi: 10.5483/BMBRep.2020.53.4.080
![]() |
[8] |
Touma M (2020) COVID-19: molecular diagnostics overview. J Mol Med (Berl) 98: 947-954. doi: 10.1007/s00109-020-01931-w
![]() |
[9] |
Huang C, Wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. doi: 10.1016/S0140-6736(20)30183-5
![]() |
[10] |
Zhou F, Yu T, Du R, et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062. doi: 10.1016/S0140-6736(20)30566-3
![]() |
[11] | Zheng F, Tang W, Li H, et al. (2020) Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 24: 3404-3410. |
[12] |
Chu DKW, Pan Y, Cheng SMS, et al. (2020) Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 66: 549-555. doi: 10.1093/clinchem/hvaa029
![]() |
[13] |
Loeffelholz MJ, Tang YW (2020) Laboratory diagnosis of emerging human coronavirus infections—the state of the art. Emerg Microbes Infect 9: 747-756. doi: 10.1080/22221751.2020.1745095
![]() |
[14] |
Emery SL, Erdman DD, Bowen MD, et al. (2004) Real-time reverse transcription-polymerase chain reaction assay for SARS-associated Coronavirus. Emerg Infect Dis 10: 311-316. doi: 10.3201/eid1002.030759
![]() |
[15] |
Wölfel R, Corman VM, Guggemos W, et al. (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465-469. doi: 10.1038/s41586-020-2196-x
![]() |
[16] |
Hans R, Marwaha N (2014) Nucleic acid testing-benefits and constraints. Asian J Transfus Sci 8: 2-3. doi: 10.4103/0973-6247.126679
![]() |
[17] | La Marca A, Capuzzo M, Paglia T, et al. (2020) Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online . |
[18] | Doi A, Iwata K, Kuroda H, et al. (2020) Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. medRxiv . |
[19] | Li Z, Yi Y, Luo X, et al. (2020) Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol 27: 25727. |
[20] | Liu R, Liu X, Han H, et al. The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis 2020 (2020) .Available from: https://doi.org/10.1101/2020.03.28.20045765. |
[21] |
Grant BD, Anderson CE, Williford JR, et al. (2020) SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents. Anal Chem 92: 11305-11309. doi: 10.1021/acs.analchem.0c01975
![]() |
[22] |
Burki TK (2020) Testing for COVID-19. Lancet Respir Med 8: e63-e64. doi: 10.1016/S2213-2600(20)30247-2
![]() |
[23] | Chen H, Ai L, Lu H, et al. (2020) Clinical and imaging features of COVID-19. Radiol Infect Dis . |
[24] |
Singh AK, Majumdar S, Singh R, et al. (2020) Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. Diabetes Metab Syndr 14: 971-978. doi: 10.1016/j.dsx.2020.06.054
![]() |
[25] |
Perez A, Jansen-Chaparro S, Saigi I, et al. (2014) Glucocorticoid-induced hyperglycemia. J Diabetes 6: 9-20. doi: 10.1111/1753-0407.12090
![]() |
[26] |
Singh AK, Singh A, Singh R, et al. (2020) Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr 14: 641-648. doi: 10.1016/j.dsx.2020.05.018
![]() |
[27] |
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. (2020) Covid-19 in Critically Ill Patients in the Seattle Region—Case Series. N Engl J Med 382: 2012-2022. doi: 10.1056/NEJMoa2004500
![]() |
[28] |
Singh AK, Singh A, Shaikh A, et al. (2020) Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 14: 241-246. doi: 10.1016/j.dsx.2020.03.011
![]() |
[29] |
Moore N (2020) Chloroquine for COVID-19 Infection. Drug Saf 43: 393-394. doi: 10.1007/s40264-020-00933-4
![]() |
[30] | Owa AB, Owa OT (2020) Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? J Microbiol Immunol Infect . |
[31] |
Uzunova K, Filipova E, Pavlova V, et al. (2020) Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomed Pharmacother 131: 110668. doi: 10.1016/j.biopha.2020.110668
![]() |
[32] | Heidary F, Gharebaghi R, et al. (2020) Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo) 1-10. |
[33] | Gupta D, Sahoo AK, Singh A (2020) Ivermectin: potential candidate for the treatment of Covid 19. Braz J Infect Dis . |
[34] |
Coomes EA, Haghbayan H (2020) Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother 75: 2013-2014. doi: 10.1093/jac/dkaa171
![]() |
[35] | Cai Q, Yang M, Liu D, et al. (2020) Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) . |
[36] | Wu R, Wang L, Kuo HD, et al. (2020) An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep 1-15. |
[37] |
Huttner BD, Catho G, Pano-Pardo JR, et al. (2020) COVID-19: don't neglect anti-microbial stewardship principles!. Clin Microbiol Infect 26: 808-810. doi: 10.1016/j.cmi.2020.04.024
![]() |
[38] |
Rawson TM, Ming D, Ahmad R, et al. (2020) Anti-microbial use, drug-resistant infections and COVID-19. Nat Rev Microbiol 18: 409-410. doi: 10.1038/s41579-020-0395-y
![]() |
[39] | Cai X, Ren M, Chen F, et al. (2020) Blood transfusion during the COVID-19 outbreak. Blood Transfus 18: 79-82. |
[40] | Kumar S, Sharma V, Priya K (2020) Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy. Am J Emerg Med . |
[41] |
Mair-Jenkins J, Saavedra-Campos M, Baillie JK (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211: 80-90. doi: 10.1093/infdis/jiu396
![]() |
[42] | Valk SJ, Piechotta V, Chai KL, et al. (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Db Syst Rev 5: CD013600. |
[43] | Hartman WR, Hess AS, Connor JP Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest (2020) .Available from: https://www.researchgate.net/publication/346772157_Hospitalized_COVID-19_Patients_treated_with_Convalescent_Plasma_in_a_Mid-size_City_in_the_Midwest. |
[44] |
Li L, Zhang W, Hu Y, et al. (2020) Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 324: 460-470. doi: 10.1001/jama.2020.10044
![]() |
[45] |
Rajarshi K, Chatterjee A, Ray S (2020) Combating COVID-19 with Mesenchymal Stem Cell therapy. Biotechnol Rep (Amst) 26: e00467. doi: 10.1016/j.btre.2020.e00467
![]() |
[46] |
Golchin A, Seyedjafari E, Ardeshirylajimi A (2020) Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Rep 16: 427-433. doi: 10.1007/s12015-020-09973-w
![]() |
[47] |
Golchin A, Farahany TZ, Khojasteh A, et al. (2018) The clinical trials of Mesenchymal stem cell therapy in skin diseases: An update and concise review. Curr Stem Cell Res Ther 14: 22-33. doi: 10.2174/1574888X13666180913123424
![]() |
[48] | Kewan T, Covut F, Al-Jaghbeer MJ, et al. (2020) Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. E Clin Med 100418. |
[49] | Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2. |
[50] | Cantini F, Niccoli L, Nannini C, et al. (2020) Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect . |
[51] |
Cantini F, Niccoli L, Matarrese D, et al. (2020) Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 81: 318-356. doi: 10.1016/j.jinf.2020.04.017
![]() |
[52] |
Maoujoud O, Asserraji M, Ahid S, et al. (2020) Anakinra for patients with COVID-19. Lancet Rheumatol 2: e383. doi: 10.1016/S2665-9913(20)30177-6
![]() |
[53] |
Filocamo G, Mangioni D, Tagliabue P, et al. (2020) Use of anakinra in severe COVID-19: A case report. Int J Infect Dis 96: 607-609. doi: 10.1016/j.ijid.2020.05.026
![]() |
[54] | Kow CS, Hasan SS (2020) Use of low-molecular-weight heparin in COVID-19 patients. J Vasc Surg Venous Lymphat Disord . |
[55] | Costanzo L, Palumbo FP, Ardita G, et al. (2020) Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J Vasc Surg Venous Lymphat Disord . |
[56] | Turshudzhyan A (2020) Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy. Cureus 12: e8150. |
[57] |
Boretti A, Banik BK (2020) Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome. PharmaNutrition 12: 100190. doi: 10.1016/j.phanu.2020.100190
![]() |
[58] |
Simonson W (2020) Vitamin C and Coronavirus. Geriatr Nurs 41: 331-332. doi: 10.1016/j.gerinurse.2020.05.002
![]() |
[59] |
Hemilä H (2003) Vitamin C and SARS coronavirus. J Antimicrob Chemother 52: 1049-1050. doi: 10.1093/jac/dkh002
![]() |
[60] | World Health Organization Draft landscape of COVID-19 candidate vaccines (2020) .Available from: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines. |
[61] |
Day M (2020) Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 369: 1375. doi: 10.1136/bmj.m1375
![]() |
[62] |
Sutton D, Fuchs K, D'Alton M, et al. (2020) Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med 382: 2163-2164. doi: 10.1056/NEJMc2009316
![]() |
[63] |
Mizumoto K, Kagaya K, Zarebski A, et al. (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 25: 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180
![]() |
[64] |
Wrapp D, Wang N, Corbett KS, et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367: 1260-1263. doi: 10.1126/science.abb2507
![]() |
[65] |
Andersen KG, Rambaut A, Lipkin WI, et al. (2020) The proximal origin of SARS-CoV-2. Nat Med 26: 450-452. doi: 10.1038/s41591-020-0820-9
![]() |
[66] |
Benvenuto D, Giovanetti M, Ciccozzi A, et al. (2020) The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol 92: 455-459. doi: 10.1002/jmv.25688
![]() |
[67] |
Yan R, Zhang Y, Li Y, et al. (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367: 1444-1448. doi: 10.1126/science.abb2762
![]() |
[68] |
Enjuanes L, Zuñiga S, Castaño-Rodriguez C, et al. (2016) Molecular Basis of Coronavirus Virulence and Vaccine Development. Adv Virus Res 96: 245-286. doi: 10.1016/bs.aivir.2016.08.003
![]() |
[69] |
Song Z, Xu Y, Bao L, et al. (2019) From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 11: 59. doi: 10.3390/v11010059
![]() |
[70] | Wu F, Wang A, Liu M, et al. (2020) Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv . |
[71] |
Thi Nhu Thao T, Labroussaa F, Ebert N, et al. (2020) Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582: 561-565. doi: 10.1038/s41586-020-2294-9
![]() |
[72] |
Xie X, Muruato A, Lokugamage KG, et al. (2020) An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27: 841-848. doi: 10.1016/j.chom.2020.04.004
![]() |
[73] |
Dicks MD, Spencer AJ, Edwards NJ, et al. (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7: e40385. doi: 10.1371/journal.pone.0040385
![]() |
[74] |
Fausther-Bovendo H, Kobinger GP (2014) Pre-existing immunity against Advectors. Hum Vaccines Immunother 10: 2875-2884. doi: 10.4161/hv.29594
![]() |
[75] |
Alberer M, Gnad-Vogt U, Hong HS, et al. (2017) Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomized, prospective, first-in-human phase 1 clinical trial. Lancet 390: 1511-1520. doi: 10.1016/S0140-6736(17)31665-3
![]() |
[76] |
Smith TRF, Patel A, Ramos S, et al. (2020) Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 11: 2601. doi: 10.1038/s41467-020-16505-0
![]() |
[77] | BIONTECH BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates (2020) .Available from: https://investors.biontech.de/node/7431/pdf. |
[78] |
Takashima Y, Osaki M, Ishimaru Y, et al. (2011) Artificial molecular clamp: A novel device for synthetic polymerases. Angew Chem Int Ed 50: 7524-7528. doi: 10.1002/anie.201102834
![]() |
[79] |
Singh K, Mehta S (2016) The clinical development process for a novel preventive vaccine: An overview. J Postgrad Med 62: 4-11. doi: 10.4103/0022-3859.173187
![]() |
[80] |
Wang Q, Zhang L, Kuwahara K, et al. (2016) Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis 2: 361-376. doi: 10.1021/acsinfecdis.6b00006
![]() |
[81] | de Sousa E, Ligeiro D, Lérias JR, et al. (2020) Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. Int J Infect Dis . |
[82] |
Li H, Liu SM, Yu XH, et al. (2020) Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 55: 105951. doi: 10.1016/j.ijantimicag.2020.105951
![]() |
[83] |
Deb B, Shah H, Goel S (2020) Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. J Biosci 45: 82. doi: 10.1007/s12038-020-00053-2
![]() |
[84] |
Abd El-Aziz TM, Stockand JD (2020) Recent progress and challenges in drug development against COVID-19 Coronavirus (SARS-CoV-2)—an update on the status. Infect Genet Evol 83: 104327. doi: 10.1016/j.meegid.2020.104327
![]() |
[85] |
Polack FP, Thomas SJ, Kitchin N, et al. (2020) C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383: 2603-2615. doi: 10.1056/NEJMoa2034577
![]() |
[86] |
Walsh EE, Frenck RW, Falsey AR, et al. (2020) Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 383: 2439-2450. doi: 10.1056/NEJMoa2027906
![]() |
[87] |
Anderson EJ, Rouphael NG, Widge AT, et al. (2020) mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med 383: 2427-2438. doi: 10.1056/NEJMoa2028436
![]() |
[88] |
Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. (2020) Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell 183: 315-323. doi: 10.1016/j.cell.2020.08.051
![]() |
[89] |
Junqueira-Kipnis AP, Dos Anjos LRB, Barbosa LCS, et al. (2020) BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 21: 881. doi: 10.1186/s13063-020-04822-0
![]() |
[90] | Rivas MN, Ebinger JE, Wu M, et al. (2021) BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers. J Clin Invest 2021 131. |
1. | Xingxing Huang, Ting Pan, Lili Yan, Ting Jin, Ruonan Zhang, Bi Chen, Jiao Feng, Ting Duan, Yu Xiang, Mingming Zhang, Xiaying Chen, Zuyi Yang, Wenzheng Zhang, Xia Ding, Tian Xie, Xinbing Sui, The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer, 2020, 23523042, 10.1016/j.gendis.2020.10.002 | |
2. | Ghiles Grine, Romain Lotte, David Chirio, Alicia Chevalier, Didier Raoult, Michel Drancourt, Raymond Ruimy, Co-culture of Methanobrevibacter smithii with enterobacteria during urinary infection, 2019, 43, 23523964, 333, 10.1016/j.ebiom.2019.04.037 | |
3. | Andreia R. Yamanaka, Alessandra T. Hayakawa, Ícaro S. M. Rocha, Valéria Dutra, Valeria R. F. Souza, José N. Cruz, Lázaro M. Camargo, Luciano Nakazato, The Occurrence of Multidrug Resistant Bacteria in the Urine of Healthy Dogs and Dogs with Cystitis, 2019, 9, 2076-2615, 1087, 10.3390/ani9121087 | |
4. | Christina M. Coleman, Daneel Ferreira, Oligosaccharides and Complex Carbohydrates: A New Paradigm for Cranberry Bioactivity, 2020, 25, 1420-3049, 881, 10.3390/molecules25040881 | |
5. | Shaokai Zheng, Dario Carugo, Ali Mosayyebi, Ben Turney, Fiona Burkhard, Dirk Lange, Dominik Obrist, Sarah Waters, Francesco Clavica, Fluid mechanical modeling of the upper urinary tract, 2021, 2692-9368, 10.1002/wsbm.1523 | |
6. | Jennifer F. Wu, Amutha Muthusamy, Gabriel A. Al-Ghalith, Dan Knights, Bin Guo, Baolin Wu, Rory P. Remmel, David P. Schladt, Maria-Luisa Alegre, William S. Oetting, Pamala A. Jacobson, Ajay K. Israni, Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients, 2018, 32, 09020063, e13436, 10.1111/ctr.13436 | |
7. | Jennifer Jones, Craig P. Murphy, Roy D. Sleator, Eamonn P. Culligan, The urobiome, urinary tract infections, and the need for alternative therapeutics, 2021, 161, 08824010, 105295, 10.1016/j.micpath.2021.105295 | |
8. | T. Sklyar, V. Gavryliuk, K. Lavrentievа, N. Kurahina, T. Lykholat, K. Zaichenko, M. Papiashvili, O. Lykholat, D. Stepansky, Monitoring of distribution of antibiotic-resistant strains of microorganisms in patients with dysbiosis of the urogenital tract , 2021, 12, 2520-2588, 199, 10.15421/022128 | |
9. | Ali Zarei, Hossein Javid, Sara Sanjarian, Sara Senemar, Hanieh Zarei, Metagenomics studies for the diagnosis and treatment of prostate cancer, 2022, 82, 0270-4137, 289, 10.1002/pros.24276 | |
10. | Shehani Jayalath, Dhammika Magana-Arachchi, Dysbiosis of the Human Urinary Microbiome and its Association to Diseases Affecting the Urinary System, 2022, 62, 0046-8991, 153, 10.1007/s12088-021-00991-x | |
11. | Hirak Ranjan Dash, Surajit Das, 2022, 118, 9780323989657, 91, 10.1016/bs.aambs.2022.02.002 | |
12. | Hae Do Jung, Joo Yong Lee, Impact of the Human Microbiome on Nephrolithiasis, 2021, 16, 2465-8243, 25, 10.14777/uti.2021.16.2.25 | |
13. | Rigoberto Pallares-Mendez, Daniel E. Cervantes-Miranda, Alejandro Diaz Gonzalez-Colmenero, Mario A. Ochoa-Arvizo, Adrian Gutierrez-Gonzalez, A Perspective of the Urinary Microbiome in Lower Urinary Tract Infections — A Review, 2022, 23, 1527-2737, 235, 10.1007/s11934-022-01108-7 | |
14. | Rachael C. Wilkinson, 2022, 9780323903035, 306, 10.1016/B978-0-12-818731-9.00055-0 | |
15. | Junjie Qin, Xulian Shi, Junming Xu, Simin Yuan, Bo Zheng, Enpu Zhang, Guixiao Huang, Guo Li, Ganggang Jiang, Shan Gao, Cheng Tian, Ruochun Guo, Zhicong Fu, Qingru Huang, Rentao Yang, Wenyong Zhang, Shenghui Li, Song Wu, Characterization of the Genitourinary Microbiome of 1,165 Middle-Aged and Elderly Healthy Individuals, 2021, 12, 1664-302X, 10.3389/fmicb.2021.673969 | |
16. | Jonathan Josephs-Spaulding, Thøger Jensen Krogh, Hannah Clara Rettig, Mark Lyng, Mariam Chkonia, Silvio Waschina, Simon Graspeuntner, Jan Rupp, Jakob Møller-Jensen, Christoph Kaleta, Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs, 2021, 11, 2235-2988, 10.3389/fcimb.2021.562525 | |
17. | Sigit Widadi, Hanifah Rahmi Fajrin, , 2022, Integration of Uroflowmetry and Database Applications Using Wireless Connection, 978-1-6654-6541-0, 369, 10.1109/ICE3IS56585.2022.10010145 | |
18. | Mangesh Suryavanshi, Mukesh Poddar, Rekha Punchappady-Devasya, 2021, Chapter 12, 978-981-16-5616-3, 253, 10.1007/978-981-16-5617-0_12 | |
19. | Alessandro Rizzo, Matteo Santoni, Veronica Mollica, Michelangelo Fiorentino, Giovanni Brandi, Francesco Massari, Microbiota and prostate cancer, 2022, 86, 1044579X, 1058, 10.1016/j.semcancer.2021.09.007 | |
20. | Xushen Chen, Ying Cheng, Xiaolin Tian, Jia Li, Xiaodong Ying, Qiuyi Zhao, Meng Wang, Yan Liu, Yulan Qiu, Xiaoyan Yan, Xuefeng Ren, Urinary microbiota and metabolic signatures associated with inorganic arsenic-induced early bladder lesions, 2023, 259, 01476513, 115010, 10.1016/j.ecoenv.2023.115010 | |
21. | Marica Colella, Skender Topi, Raffaele Palmirotta, Donato D’Agostino, Ioannis Alexandros Charitos, Roberto Lovero, Luigi Santacroce, An Overview of the Microbiota of the Human Urinary Tract in Health and Disease: Current Issues and Perspectives, 2023, 13, 2075-1729, 1486, 10.3390/life13071486 | |
22. | Yoon Jae Cho, Bokyoung Shin, Sung-Ha Lee, Sangmin Park, Yoon-Keun Kim, Jae-Jin Kim, Eunjoo Kim, Altered Urine Microbiome in Male Children and Adolescents with Attention-Deficit Hyperactivity Disorder, 2023, 11, 2076-2607, 2063, 10.3390/microorganisms11082063 | |
23. | Bernardita M. Ljubetic, Ashu Mohammad, Butool Durrani, Amy D. Dobberfuhl, Pathophysiologic Insights into the Transition from Asymptomatic Bacteriuria to Urinary Tract Infection, 2023, 1527-2737, 10.1007/s11934-023-01183-4 | |
24. | Elham Emami, Catherine MT Sherwin, Saeid Heidari-Soureshjani, Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis, 2024, 19, 27724328, 111, 10.2174/2772432817666220501114505 | |
25. | Kishore Kumar Godisela, Pallaval Veera Bramhachari, 2023, Chapter 11, 978-981-99-5113-0, 205, 10.1007/978-981-99-5114-7_11 | |
26. | Joie Ling, Andrew J. Hryckowian, Anthony R. Richardson, Re-framing the importance of Group B Streptococcus as a gut-resident pathobiont , 2024, 0019-9567, 10.1128/iai.00478-23 | |
27. | Magdalena Jendraszak, Izabela Skibińska, Małgorzata Kotwicka, Mirosław Andrusiewicz, The elusive male microbiome: revealing the link between the genital microbiota and fertility. Critical review and future perspectives, 2024, 1040-8363, 1, 10.1080/10408363.2024.2331489 | |
28. | Patrick Joubran, Françoise A. Roux, Matteo Serino, Jack-Yves Deschamps, Gut and Urinary Microbiota in Cats with Kidney Stones, 2024, 12, 2076-2607, 1098, 10.3390/microorganisms12061098 | |
29. | Abdolah Razi, Azita Ghiaei, Fahimeh Kamali Dolatabadi, Ramin Haghighi, Unraveling the association of bacteria and urinary stones in patients with urolithiasis: an update review article, 2024, 11, 2296-858X, 10.3389/fmed.2024.1401808 | |
30. | Amal Naji, Drew Siskin, Michael H Woodworth, John R Lee, Colleen S Kraft, Nirja Mehta, The Role of the Gut, Urine, and Vaginal Microbiomes in the Pathogenesis of Urinary Tract Infection in Women and Consideration of Microbiome Therapeutics, 2024, 11, 2328-8957, 10.1093/ofid/ofae471 | |
31. | Pallabi Chatterjee, Isra Aman Aziz, Amarjit Singh, Aditi Singh, 2024, 9789815274431, 1, 10.2174/9789815274431124010003 | |
32. | Jayaprakash Sasikumar, Rumaisa Ali Ebrahim, Shankar Prasad Das, Diverse Colonisation and Disease Associations of the Human Commensal Malassezia: Our Body's Secret Tenant, 2025, 68, 0933-7407, 10.1111/myc.70014 |